Farag Kameel D. 4

What Happened
Farag Kameel, Interim Chief Financial Officer of Akari Therapeutics Plc (AKTX), received awards in the form of American Depositary Shares (ADS) reported as restricted stock units (RSUs) that vested in full on June 24, 2026. The filing reports seven award tranches totaling 18,830 ADS with an aggregate reported value of approximately $105,006. This was an award/vesting event (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely filing).
• Reported tranches:
  • 1,248 ADS @ $10.02 = $12,505
  • 1,395 ADS @ $9.32 = $13,001
  • 1,570 ADS @ $8.28 = $13,000
  • 2,539 ADS @ $5.12 = $13,000
  • 3,725 ADS @ $3.49 = $13,000
  • 7,353 ADS @ $3.74 = $27,500
  • 1,000 ADS @ $13.00 = $13,000
• Total ADS received (vested): 18,830; total reported value: ~$105,006.
• Shares owned after transaction: not specified in the Form 4.
• Footnote: The filing states these ADS represent RSUs, and each such RSU "represents the right to receive 80,000 ordinary shares" (par value $0.000000005). The RSUs vested in full on June 24, 2026.
• No 10b5-1 plan, tax-withholding sale, or late filing indicated in the report.

Context
RSU vesting is a compensation event that results in the insider receiving (or becoming entitled to) shares; it is neither a purchase nor a sale and does not by itself signal buying or selling sentiment. For derivative-type awards like RSUs, check the footnotes for settlement terms — here the filing notes an unusual conversion ratio (each RSU tied to 80,000 ordinary shares), which investors may want to confirm from company disclosures or future filings for clarification.